Label-free Assessment of Complement-Dependent Cytotoxicity of Therapeutic Antibodies via a Whole-Cell MALDI Mass Spectrometry Bioassay
S. Schmidt, A. Geisel, T. Enzlein, B. C. Froehlich, L. Pritchett, M. Verneret, C. Graf, C. Hopf
This study develops a label-free MALDI-TOF mass spectrometry bioassay to assess complement-dependent cytotoxicity of Rituximab, identifying metabolite markers and demonstrating robust concentration-response characteristics.
bioRxiv · May 3, 2024Biochemistry